Skip to main content
Assets
Ginkgo Bioworks logo
DNA.NYSE
Ginkgo Bioworks
Health Care · Biotechnology

Synthetic biology platform company programming cells for biotechnology, pharmaceuticals, agriculture, and industrial applications.

HQ: United StatesListed: United States

Profile & Fundamentals

Ginkgo Bioworks: Company identity, ownership, reported financial performance, balance sheets, and corporate actions.

Profile & Fundamentals

Ginkgo Bioworks Profile & Fundamentals

Examine company identity, ownership, reported performance, valuation, balance-sheet resilience, dividends, buybacks, and material corporate events.

Interactive annual & quarterly chartsAI financial reviewsReported source tables
Explore this pageJump to a Profile & Fundamentals section

Explore this research

Profile & Fundamentals contents

Company and Market Context

Company Profile & Ownership

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

DNA.NYSE

Company profile record

Ginkgo Bioworks Holdings

Common Stock · Health Care · Biotechnology

Official website

Company

Company / asset
Ginkgo Bioworks Holdings
Security type
Common Stock
Sector
Health Care
Industry
Biotechnology
HQ
🇺🇸 United States
Head office
27 Drydock Avenue, Boston, MA, United States, 02210

Leadership & scale

Chief executive
Dr. Jason Kelly Ph.D.
CEO year born
1981
Full-time employees
485
Fiscal year end
December
IPO date
2021-04-19

Fundamentals snapshot

Updated 2026-09-13
Market Cap
USD 661.9M
P/E
--
Revenue (Q2 26)
USD 20.2M
Profit (Q2 26)
USD -46.7M
Dividend Yield
--
Revenue (FY 25)
USD 170.2M
Shares in public float
49.9M
Insider ownership
4.43%

Reporting & identifiers

Symbol
DNA.NYSE
Listing
🇺🇸 United States | Dividend Tax: 30%
Ticker Currency
USD
Income Statement Currency
USD
Balance Sheet Currency
USD
Cash Flow Currency
USD
EPS Currency
USD
Contract Type
SPOT
ISIN
US37611X2099
Asset ID
equity_d620e41c-a941-50d1-953a-a198ca15eb5f

Ownership

Shares Outstanding

Shares OutstandingAnnual reported shares outstanding. Values in shares.25.69M35.62M45.55M55.48M65.4MJan 2019Oct 2020Jul 2022Apr 2024Jan 2026
  • Shares outstanding
Annual reported shares outstanding. Values in shares.

Top holders

  1. BlackRock Inc3,642,347 shares · 5.41% · Reported 2026-03-31
  2. Viking Global Investors LP3,577,128 shares · 5.31% · Reported 2026-03-31
  3. Baillie Gifford & Co Limited.2,391,649 shares · 3.55% · Reported 2026-06-30
  4. Scottish Mortgage Ord2,391,649 shares · 3.55% · Reported 2026-07-31
  5. Erste Asset Management GmbH1,947,728 shares · 2.89% · Reported 2026-03-31
  6. Vanguard Capital Management, LLC1,914,428 shares · 2.84% · Reported 2026-03-31
  7. Anchorage Advisors, LLC1,746,363 shares · 2.59% · Reported 2026-06-30
View more holders (8)
  1. Legal & General Group PLC1,661,587 shares · 2.47% · Reported 2026-03-31
  2. L&G Artificial Intelligence ETF1,632,208 shares · 2.42% · Reported 2026-08-31
  3. Vanguard MStar Total Stk Mkt Idx Invest1,489,851 shares · 2.21% · Reported 2026-07-31
  4. State Street Corp1,346,659 shares · 2.00% · Reported 2026-03-31
  5. iShares Russell 2000 ETF1,232,832 shares · 1.83% · Reported 2026-08-31
  6. Geode Capital Management, LLC1,009,362 shares · 1.50% · Reported 2026-03-31
  7. Forbes J M & Co999,911 shares · 1.48% · Reported 2026-06-30
  8. The Goldman Sachs Group Inc929,862 shares · 1.38% · Reported 2026-03-31

Earnings, Profitability & Valuation

Earnings & Revenue

Revenue, Net Income, and Free Cash Flow

Revenue, Net Income, and Free Cash FlowAnnual reported financial results, converted using the statement's recorded USD conversion. Missing values are omitted. Values in USD.-2.36B-1.59B-813.61M-38.82M735.97MDec 2019Jul 2021Dec 2022Jul 2024Dec 2025
  • Revenue
  • Free cash flow
  • Net income
Annual reported financial results, converted using the statement's recorded USD conversion. Missing values are omitted. Values in USD.

Valuation

Historical P/E Ratio

The published data is insufficient to draw this chart.

Profitability & Margins

Profitability Margins

Profitability MarginsAnnual gross, operating, net income and free cash flow divided by revenue for matching reporting dates. Values in percent.-651.43-446.5-241.56-36.62168.31Dec 2019Jul 2021Dec 2022Jul 2024Dec 2025
  • Gross margin
  • Operating margin
  • Net margin
  • Free cash flow margin
Annual gross, operating, net income and free cash flow divided by revenue for matching reporting dates. Values in percent.

Complete Research Workspace

Unlock the complete Profile & Fundamentals

Sign in to verify your access, or upgrade to the Base plan to open the complete profile & fundamentals and available source data.

Ginkgo Bioworks (DNA) Financials, Profile & Valuation | iPulse AI